Zyprexa Relprevv and Breastfeeding
Studies have shown that Zyprexa Relprevv (olanzapine extended-release injection) is passed through breast milk. Due to the potentially serious risks this drug may pose to a breastfed infant, the manufacturer recommends that women not breastfeed during treatment with Zyprexa Relprevv. To avoid negative side effects in your baby, talk to your healthcare provider prior to receiving this medication.
Zyprexa® Relprevv™ (olanzapine extended-release injection) is a prescription long-acting medication used in the treatment of schizophrenia. It is passed through breast milk. The manufacturer of Zyprexa Relprevv recommends that women not breastfeed during treatment.
Olanzapine, the active ingredient in Zyprexa Relprevv, has been studied in breastfeeding women. Based on the results of these studies, the drug is known to pass through breast milk.
There have been several reports of infants who breastfed while their mothers were on olanzapine without developing any problems. However, there have also been cases of infants experiencing sedation, diarrhea, and diaper rash. In addition, jaundice (yellowing of the skin and whites of the eyes) and heart murmurs have been reported in nursing infants whose mothers took this drug, but it is not entirely clear whether these effects were due to olanzapine or something else.
Because Zyprexa Relprevv remains in the body for an extended period of time, it may be safest to avoid breastfeeding during treatment. If your healthcare provider recommends taking the medicine while nursing, make sure to watch for any possible Zyprexa Relprevv side effects in your child, including sedation and jaundice. If you would like to breastfeed after stopping Zyprexa Relprevv, talk to your healthcare provider about how long you should wait between receiving your last dose and beginning to breastfeed.